Page last updated: 2024-11-08

org 31710

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Org 31710: structure given in first source; progestational hormone antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164090
CHEMBL ID460258
SCHEMBL ID3270952
MeSH IDM0205000

Synonyms (20)

Synonym
org-31710
118968-41-5
org 31710
spiro(estra-4,9-diene-17,2'(3'h)-furan)-3-one, 11-(4-(dimethylamino)phenyl)-4',5'-dihydro-6-methyl-, (6beta,11beta,17beta)-
11-(4-dimethylaminophenyl)-6-methyl-4',5'-dihydro(estra-4,9-diene-17,2'-(3h)-furan)-3-one
CHEMBL460258
unii-x2v3mg6pe8
x2v3mg6pe8 ,
spiro[estra-4,9-diene-17,2'(3'h)-furan]-3-one,11-[4-(dimethylamino)phenyl]-4',5'-dihydro-6-methyl-, (6b,11b,17b)-
SCHEMBL3270952
org31710
11-[4-(dimethylamino)phenyl]-6,13-dimethyl-1,6,7,8,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phenanthrene-17,2'-oxolan]-3(2h)-one
DTXSID70922821
(6r,8s,11r,13s,14s,17r)-11-(4-(dimethylamino)phenyl)-6,13-dimethyl-1,4',5',6,7,8,11,12,13,14,15,16-dodecahydro-3'h-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3(2h)-one
DB15585
(6r,8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-6,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one
(6.beta.,11.beta.,17.beta.)-11-(4-(dimethylamino)phenyl)-4',5'-dihydro-6-methylspiro(estra-4,9-diene-17,2'(3'h)-furan)-3-one
spiro(estra-4,9-diene-17,2'(3'h)-furan)-3-one, 11-(4-(dimethylamino)phenyl)-4',5'-dihydro-6-methyl-, (6.beta.,11.beta.,17.beta.)-
(6r,8s,11r,13s,14s,17r)-11-(4-(dimethylamino)phenyl)-6,13-dimethyl-1,4',5',6,7,8,11,12,13,14,15,16-dodecahydro-3'h-spiro(cyclopenta(a)phenanthrene-17,2'-furan)-3(2h)-one
AKOS040749091

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No adverse or seriously adverse events were observed."( Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers.
Bennink, HJ; Bobbink, IW; Mink, CP; Mulders, TM, 1998
)
0.53
" All dosages were well tolerated and no clinically relevant adverse events were recorded."( Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers.
Bennink, HJ; Bobbink, IW; Mink, CP; Mulders, TM, 1998
)
0.53

Pharmacokinetics

The plasma pharmacokinetic characterizations revealed a statistically significant deviation from linearity after single doses of 10-75 mg of Org 31710. The dose normalized Cmax and dose normalized area under the curve were significantly lower for the higher dosages.

ExcerptReferenceRelevance
" Plasma pharmacokinetic characterizations revealed a statistically significant deviation from linearity after single doses of 10-75 mg of Org 31710."( Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers.
Bennink, HJ; Bobbink, IW; Mink, CP; Mulders, TM, 1998
)
0.73
" Using the rationale of the BCS, it can be argued that biowaivers can, however, also be granted on the basis of standard pharmacokinetic data."( Biowaivers for oral immediate-release products: implications of linear pharmacokinetics.
Faassen, F; Vromans, H, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" In conclusion, Org 31710 appears to be a safe and well-tolerated compound in the dosage range studied."( Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers.
Bennink, HJ; Bobbink, IW; Mink, CP; Mulders, TM, 1998
)
0.87
" Cycle control is better at low than at high doses of antiprogestin in combination with daily dosing of 4 microg/kg desogestrel."( Preclinical experience with two selective progesterone receptor modulators on breast and endometrium.
Deckers, GH; Hanssen, RG; Hodgen, GD; Hsiu, JG; Kloosterboer, HJ; Rose, UM; Schoonen, WG; Verbost, PM; Williams, RF,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID343233Progestational activity in estrone-treated ovariectomized rat assessed as inhibition of medroxyprogesterone acetate-induced reduction of breast alveolar bud proliferation2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID343232Progestational activity in estrone-treated ovariectomized rat assessed as inhibition of medroxyprogesterone acetate-induced effect on vaginal epithelial thickness2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID343231Progestational activity in estrone-treated ovariectomized rat assessed as inhibition of medroxyprogesterone acetate-induced effect on uterine epithelial cell height2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (27.03)18.2507
2000's20 (54.05)29.6817
2010's7 (18.92)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.66 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (7.89%)5.53%
Reviews2 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (86.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]